Enliven Therapeutics
PublicEnliven Therapeutics is now publicly traded
The data on this page reflects Enliven Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Follow-on Offering
Jun 16, 2025
Total Funding Raised
$540M
Company Overview
Enliven Therapeutics (NAS: ELVN) is a clinical-stage precision oncology company specializing in the discovery and development of innovative therapies aimed at addressing challenges in cancer treatment, including tolerability and resistance.
Sector
Healthcare/Wellness
AI Layer
Non-AI
Keywords
Enliven Therapeutics Comparables
Compare Enliven Therapeutics with similar companies based on industry and business-model similarity.
No public comparables are available for Enliven Therapeutics. Request access to learn about comparables coverage.
Request accessEnliven Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Follow-on Offering | Jun 16, 2025 | ||||
| Private Placement | Mar 21, 2024 | ||||
| Reverse Merger | Feb 23, 2023 | ||||
| Series A | Dec 7, 2020 |
Enliven Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jefferies | Follow-on Offering |
| Janus Henderson Group | Series A |
| RA Capital Management | Reverse Merger |
| Fidelity Management & Research Company | Reverse Merger |
| Fairmount Ventures | Reverse Merger |
| OrbiMed | Series A |
| 5AM Ventures | Series A |
Enliven Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access